# Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer

## TL;DR

Trimodal therapy for bladder cancer improves quality of life but is not cost-effective compared to radical cystectomy due to higher treatment costs.

## Contribution

This study provides a novel economic evaluation comparing trimodal therapy and radical cystectomy for muscle-invasive bladder cancer.

## Key findings

- Trimodal therapy had higher costs but similar or slightly better quality-adjusted life years compared to radical cystectomy.
- Trimodal therapy was not cost-effective at 5- or 10-year time horizons due to high incremental cost-effectiveness ratios.
- Cost reductions or improved outcomes in trimodal therapy could make it cost-effective.

## Abstract

What is the more cost-effective strategy for management of muscle-invasive bladder cancer?

In this economic evaluation, trimodal therapy was associated with improved quality of life, but was not a cost-effective strategy for management of muscle-invasive bladder cancer relative to radical cystectomy.

Policy initiatives are needed to reduce the cost of trimodal therapy, and discussions about long-term tradeoffs of toxic effects between radical cystectomy and trimodal therapy are critical to guide preference-sensitive care.

This economic evaluation compares the cost-effectiveness of treatment and disease management strategies for muscle-invasive bladder cancer from a US payer perspective.

Trimodal therapy (TMT) is included as an alternative to radical cystectomy (RC) for definitive management of muscle-invasive bladder cancer (MIBC) in current clinical guidelines. Moreover, a 2023 retrospective analysis reported similar oncologic outcomes between these treatments among patients deemed fit for RC. Data regarding the comparative value of these treatments are lacking.

To evaluate the comparative cost-effectiveness of TMT and RC for treatment of MIBC.

This economic evaluation compared cost-effectiveness of treatments using a health transition state microsimulation model of patients with bladder cancer treated between 2005 and 2017 with 5- and 10-year horizons from a Medicare perspective. Model probabilities were informed by multicenter retrospective analyses published in 2023 comparing TMT with RC. The index patient was aged 71 years, with clinical stage T2-4aN0M0 MIBC, solitary tumor smaller than 7 cm, no or unilateral hydronephrosis, adequate bladder function, and lack of multifocal or extensive carcinoma in situ. Patients unfit for RC, radiation, or cisplatin-based chemotherapy were excluded.

TMT and RC.

Primary outcomes included effectiveness measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $100 000 per QALY. Sensitivity analyses were performed to assess the robustness of the model.

For the index patient, at 5 years, the average cost was $30 525 higher for TMT than RC. Average QALYs were 3.87 and 3.94 for RC and TMT, respectively. As such, TMT was not cost-effective at 5-year (ICER, $464 291 per QALY) or 10-year (ICER, $308 638 per QALY) time horizons. On 1-way sensitivity analyses, TMT would become cost-effective if (1) TMT costs were less than $17 605; or (2) TMT resulted in an 11.6% improvement in metastasis-free survival relative to RC.

In this economic evaluation study of TMT and RC for treatment of MIBC, TMT was associated with improved quality of life but was not cost-effective relative to RC at 5 and 10 years given higher treatment costs. These findings highlight the importance of developing policy initiatives that help reduce TMT costs and of providing patients with accurate expectations of long-term toxic effects to help guide preference-sensitive care.